KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Liabilities (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Total Liabilities for 8 consecutive years, with $767.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 4.82% year-over-year to $767.9 million, compared with a TTM value of $767.9 million through Dec 2025, up 4.82%, and an annual FY2025 reading of $767.9 million, up 4.82% over the prior year.
  • Total Liabilities was $767.9 million for Q4 2025 at Esperion Therapeutics, down from $815.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $815.4 million in Q3 2025 and bottomed at $548.0 million in Q1 2021.
  • Average Total Liabilities over 5 years is $652.0 million, with a median of $619.1 million recorded in 2022.
  • The sharpest move saw Total Liabilities soared 142.95% in 2021, then decreased 1.76% in 2023.
  • Year by year, Total Liabilities stood at $578.5 million in 2021, then decreased by 1.18% to $571.7 million in 2022, then rose by 15.58% to $660.8 million in 2023, then rose by 10.86% to $732.5 million in 2024, then rose by 4.82% to $767.9 million in 2025.
  • Business Quant data shows Total Liabilities for ESPR at $767.9 million in Q4 2025, $815.4 million in Q3 2025, and $780.6 million in Q2 2025.